Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03108885 · ClinicalTrials.gov registry record
Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
A clinical trial, sponsored by Mayo Clinic.
- Terminated
- Registry status
- 11
- Enrollment target
NCT03108885: Clinical Trial study, sponsored by Mayo Clinic.
NCT03108885 is a clinical trial that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03108885 was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- 11 participants
- Enrollment target
Study Summary
To prospectively collect blood and tumor tissue from esophageal cancer patients to identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence.
Interventions
- OTHER Blood and Tissue Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2020-05-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03108885
The ClinicalTrials.gov registry entry for NCT03108885 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood and Tissue Collection is the first listed.
NCT03108885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03108885 about?
NCT03108885 is a clinical study titled "Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence". To prospectively collect blood and tumor tissue from esophageal cancer patients to identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence.
What is the current status of trial NCT03108885?
This trial is currently terminated. The enrollment target is 11 participants. The study started on 2017-10-01. Estimated completion is 2020-05-25.
What interventions are being tested in trial NCT03108885?
The interventions under investigation include: Blood and Tissue Collection (OTHER).
Who is sponsoring clinical trial NCT03108885?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.